Project Grant R43HL176246
Award Date
8/20/24
Completion Date
7/31/25
Dollars Obligated
$307K
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Texas, USA
Similar Awards
This federal Project Grant award of $680,583 from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) to Mayo Clinic supports research focused on discovering genetic modifiers and therapies for anthracycline-induced cardiotoxicity. The key objectives are to: Confirm FABP7 and GPNMB as therapeutic target genes for anthracycline-induced cardiotoxicity, and explore the role of cardiac aging using the killifish model. Test the hypothesis that epicardial...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), part of the Cardiovascular Diseases Research program (CFDA 93.837), provides $300,000 to Gigamune, Inc. to develop an in vivo gene therapy for sickle cell disease. The project aims to test a novel lentiviral vector technology for efficiently editing hematopoietic stem cells to knockout the BCL11A enhancer, a key genetic target for sickle cell treatment. Through in vitro assays, the Phase I effort will...
This Project Grant awarded by the National Heart, Lung, and Blood Institute (NHLBI) under CFDA 93.837 - Cardiovascular Diseases Research provides $2,469,283 to the University of Kansas Medical Center Research Institute, Inc. (KUMCRI) to develop novel gene editing therapies for cystic fibrosis (CF). The project aims to use a homology-independent targeted integration (HITI) approach to permanently correct mutations in the CFTR gene and restore functional CFTR expression in airway epithelial cells,...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $814,209 to the Fred Hutchinson Cancer Center (doing business as Seattle Cancer Care Alliance) to develop CD90-targeted nanoparticles for in vivo hematopoietic stem cell gene therapy. The key objectives are to: 1) optimize nanoparticle formulations loaded with gene-editing agents and functionalize them for targeting, 2) evaluate the...
This Project Grant award from the National Heart Lung and Blood Institute (CFDA Program 93.837 - Cardiovascular Diseases Research) provides $549,796 to Cedars-Sinai Medical Center to conduct research focused on understanding how mutations in the TET2 and IDH2 genes associated with acute myeloid leukemia (AML) can impact cardiac metabolism and lead to cardiomyopathy and heart failure. The key research objectives are to: 1) Examine alterations in heart oxidative metabolism in response to TET2 or...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $299,995 Project Grant under the Cardiovascular Diseases Research (CFDA 93.837) program to Nanite Inc., a small disadvantaged business in Massachusetts. The grant will fund the development of computationally-designed polymer-based delivery vehicles for mRNA payloads to treat cystic fibrosis (CF), a debilitating genetic disorder affecting the lungs. The project aims to leverage computational modeling and high-throughput polymer...
This federal Project Grant award, valued at $166,644.00 and awarded by the National Heart Lung and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), supports research to investigate the functional and molecular consequences of aging and TET2 mutations on human hematopoietic stem cell responses to inflammatory cytokines like IL-1β. The research aims to provide a comprehensive understanding of how these factors alter inflammatory response pathways, leading...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) is focused on conducting definitive (GLP) toxicity and toxicology studies for a novel small molecule therapy to protect against cardiotoxicity in triple negative breast cancer (TNBC) patients. The $1,000,000 award will support the development and commercialization of this novel, safe, and effective therapy that synergizes with anthracyclines, such...
This $888,000 project grant from the National Heart, Lung and Blood Institute will fund research into the role of oxidative signaling through Na/K-ATPase in chronic kidney disease-induced anemia. The awardee, Marshall University Research Corporation, will investigate how accelerated red blood cell eryptosis, or premature cell death, contributes to anemia development and progression in chronic kidney disease. Two specific aims will be pursued: 1) defining the role of adipocytes and global...
This federal Project Grant award, provided by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), supports the development of selective degradation strategies to target mutant transcription factors. The $253,500.00 award will fund experiments to design and test approaches to selectively degrade the mutant variant of the KLF1 transcription factor, which is implicated in...